XSHE
300501
Market cap505mUSD
Jul 10, Last price
12.19CNY
1D
-1.14%
1Q
-31.86%
Jan 2017
-66.77%
IPO
-0.92%
Name
Shanghai Haishun New Pharmaceutical Packaging Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
HySum Flexibles Global, Inc. operates as a manufacturer, distributor, and international exporter of packaging solutions, with a primary focus on the pharmaceutical sector. The company's reach extends throughout China and into global markets. Its extensive catalog for pharmaceutical packaging features products such as cold-form and tropical foils, PVC/Aclar sheets, PTP lidding, and a variety of "hipack" offerings like child-resistant packaging, AL/PE strip packs, complex laminated flexible films, and AL/PE suppository laminates. Additional items include lamination foil and pouches, composite films, PVC, PVDC/PVC pharmaceutical packaging, PE series bags, and bottles crafted from PP, PE, and COP materials. Beyond pharmaceuticals, HySum also caters to the food industry, supplying three-layer co-extruded PE films, high-barrier films produced via top-blown and bottom-blown multi-layer co-extrusion, and multi-layer co-extruded sheets. The company further supports the new energy material sector with specialized aluminum plastic films. Its precision injection packaging division delivers products such as precision injection molded packaging, desiccant combinations, exact dosing devices, diagnostic reagent packages, and both plastic and high-barrier vaccine vials. Established in 2005, the company was formerly known as Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. It officially rebranded to HySum Flexibles Global, Inc. in January 2024. The corporate headquarters are situated in Shanghai, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||